Document Preview Unavailable
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
Han Jiaqi; Xiao Desheng; Tan Chongqing; Zeng Xiaohui; Hu Huabin; et al. Cancer Control Vol. 27, Iss. 1, (Jan 2020).You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library